Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 0.68 |
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.68 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.68 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.68 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.67 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.67 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.68 |
| ▸ | HTR2B | P41595 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | HTR1A | P08908 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL1770432 | 0.89 | ADRB1 (0.63) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL4667366 | 0.87 | ADRB1 (0.67) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL5885719 | 0.86 | ADRB2 (0.62) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL9837071 | 0.84 | ADRB2 (0.69) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL9837906 | 0.83 | ADRB2 (0.68) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL10356800 | 0.83 | ADRB1 (1.00) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL41231 | 0.83 | ADRB1 (1.00) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL10882744 | 0.83 | ADRB1 (1.00) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Dilevalol SCHEMBL79468 | 0.83 | ADRB1 (1.00) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A | |
| Labetalol SCHEMBL4582 | 0.83 | ADRB1 (1.00) | ADRB1ADRB2ALDH1A1CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301186-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2011-12-08 | — | — | US | disclosed |
| US-20110288013-A1 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2011-11-24 | — | — | US | disclosed |
| EP-2215262-A2 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2010-08-11 | — | — | EP | disclosed |
| EP-2158333-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF DEFECTIVE REVERSE CHOLESTEROL TRANSPORT (RCT) | Synvista Therapeutics, Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090246770-A1 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-10-01 | — | — | US | disclosed |
| US-20090137617-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE | BBDX, INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009057119-A2 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-05-07 | — | — | WO | disclosed |
| US-20090074740-A1 | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2009-03-19 | — | — | US | disclosed |
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | LEVY ANDREW | 2009-02-26 | — | — | US | disclosed |
| US-20090018110-A1 | Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH) | LEVY ANDREW | 2009-01-15 | — | — | US | disclosed |
| WO-2008153908-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF INTRAPLAQUE HEMORRHAGE | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153906-A1 | HAPTOGLOBIN GENOTYPING FOR PROGNOSIS AND TREATMENT OF CHRONIC VASOSPASM FOLLOWING SUBARACHNOID HEMORRHAGE (SAH) | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008143883-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF DEFECTIVE REVERSE CHOLESTEROL TRANSPORT (RCT) | SYNVISTA THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008143879-A2 | VITAMIN E SUPPLEMENTATION FOR REDUCING CARDIOVASCULAR EVENTS IN INDIVIDUALS WITH DM AND THE HP 2-2 GENOTYPE | SYNVISTA THERAPEUTICS, INC (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080213785-A1 | Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals | BBDX, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080044399-A1 | Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype | BBDX, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018110-A1 | Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH) | HMOX1, GSTA2, SERPINA6 | ADRB1 676/4885ADRB2 920/4885ADRA1A 990/4885 |
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | APOB, PPHLN1, SERPINC1 | ADRB1 1533/4885ADRB2 1770/4885ADRA1A 1694/4885 |
| US-20080044399-A1 | Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype | HBG2, HMOX2, HBG1 | ADRB1 2672/4885ADRB2 1545/4885ADRA1A 3549/4885 |
| US-20110301186-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE | GSTA2, PON1, APOB | ADRB1 2400/4885ADRB2 1600/4885ADRA1A 3028/4885 |
| US-20090074740-A1 | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT) | CETP, ABCB4, HDLBP | ADRB1 540/4885ADRB2 1102/4885ADRA1A 1167/4885 |
| US-20090137617-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE | GSTA2, PON1, APOB | ADRB1 2400/4885ADRB2 1600/4885ADRA1A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.